Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate f...
-SEC Filing
On September 28, 2025, Jaguar Health, Inc. (the "Company") entered into a securities purchase agreement (the "Purch...
Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, toda...
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant ...
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatm...
